Introduction: Radiation therapy plays an important role in the treatment of localized breast cancer. Hypofractionated (HF) radiation therapy has emerged as a promising alternative to conventional fractionation (CF) schedules, offering comparable efficacy with reduced treatment duration and costs. However, concerns remain regarding its safety and rate of toxicity, particularly in patients undergoing mastectomy with breast reconstruction. This study aimed to assess the implant-related complications in breast cancer patients receiving HF post-mastectomy radiation therapy (PMRT) and reconstruction compared to CF PMRT. Methods: A retrospective study was conducted on 59 breast cancer patients who underwent mastectomy and breast reconstruction between 2013 and 2021 and received adjuvant PMRT. Patient demographics, treatment characteristics, and implant-related complications were analyzed. Statistical tests including chi-square, Fischer’s exact test, and multivariable Cox regression were employed for analysis. Results: Of the 59 patients, 29 received HF PMRT and 30 received CF PMRT. At a median follow-up of 23.4 months, there was no significant difference in major implant-related complications between the two groups (24.1% in HF vs. 33.3% in CF,p= 0.436). Most complications in the HF group occurred within the first two years post-radiation. Age over 40 was identified as a significant predictor for higher implant-related complications (p= 0.029). Conclusions: Our findings indicate that HF PMRT and reconstruction does not increase the risk of major implant-related complications compared to CF PMRT. These results align with the existing literature, supporting the safety of HF radiation in breast cancer patients who underwent mastectomy with reconstruction.
引言：放射治疗在局限性乳腺癌的治疗中扮演重要角色。与传统分割放疗方案相比，大分割放疗以其相当的疗效、更短的治疗周期和更低的治疗成本，成为一种前景广阔的替代方案。然而，关于其安全性及毒性反应率，尤其是在接受乳房切除联合乳房重建术的患者中，仍存在疑虑。本研究旨在评估接受乳房切除术后大分割放疗联合重建术的乳腺癌患者，与传统分割放疗相比，其植入物相关并发症的发生情况。方法：本研究回顾性分析了2013年至2021年间接受乳房切除术、乳房重建术及术后辅助放疗的59例乳腺癌患者。分析了患者人口统计学特征、治疗特点及植入物相关并发症。采用卡方检验、Fisher精确检验及多变量Cox回归等统计方法进行分析。结果：在59例患者中，29例接受大分割放疗，30例接受传统分割放疗。中位随访时间为23.4个月，两组间主要植入物相关并发症发生率无显著差异（大分割组24.1% vs. 传统分割组33.3%，p=0.436）。大分割组的大多数并发症发生在放疗后两年内。年龄超过40岁被确定为植入物相关并发症发生率较高的显著预测因素（p=0.029）。结论：我们的研究结果表明，与传统分割放疗相比，大分割放疗联合重建术并未增加主要植入物相关并发症的风险。这些结果与现有文献一致，支持大分割放疗在接受乳房切除联合重建术的乳腺癌患者中的安全性。
肿瘤(癌症)患者之家